Previous 10 | Next 10 |
Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced the submission of its New Drug Application (NDA) to the U.S. Food and Drug Administration...
Glaukos Corporation (GKOS) Q4 2022 Earnings Conference Call February 22, 2023 4:30 PM ET Company Participants Chris Lewis – Vice President-Investor Relations and Corporate Affairs Tom Burns – Chief Executive Officer Alex Thurman – Chief Financial O...
Glaukos press release ( NYSE: GKOS ): Q4 Non-GAAP EPS of -$0.53 beats by $0.02 . Revenue of $71.22M (-2.7% Y/Y) beats by $3.15M . Glaucoma net sales of $52.9 million and Corneal Health net sales of $18.3 million in Q4 2022. Introduced 2023 net sales guidance range ...
Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced financial results for the fourth quarter and full year ended December 31, 2022. Key highl...
Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced that its management is scheduled to participate in the Citi Healthcare Conference on Wedn...
Summary The market continues to chase strong profitability metrics as it always has done. Glaukos continues to exhibit positive clinical trial momentum, yet hasn't been rewarded by investors on this. Part of the debate is centred around the heavy reinvestment of adjusted operating i...
Conference Call and Webcast Scheduled for 1:30 p.m. PT Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, plans to release fourth quarter and full...
Initial results from a phase 2a trial of Glaukos Corp. ( NYSE: GKOS ) GLK-301 showed an improvement in the quality of tear film and in quality of vision for dry eye disease. The company plans on advancing the candidate into phase 2b. In the study, three different dose lev...
Commencement of Subject Enrollment in Epioxa™ Phase 3 Confirmatory Trial Promising Phase 2a Results for GLK-301 (iLution – Dry Eye Disease) Support Planned Phase 2b Study to Commence in 2023 Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pha...
Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced positive results for a prospective, multi-center clinical trial designed to evaluate the ...
News, Short Squeeze, Breakout and More Instantly...
Conference Call and Webcast Scheduled for 1:30 p.m. PT Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, plans to release second quarter 2024 fin...
Shares of Glaukos Corporation (NYSE: GKOS) traded at a new 52-week high today and are currently trading at $120.11. So far today, approximately 152.81k shares have been exchanged, as compared to an average 30-day volume of 541.53k shares. Glaukos Corporation, an ophthalmic medical technology ...
2024-07-01 22:40:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...